WuXi Vaccines, a subsidiary of WuXi Biologics, has named Jian Dong as its new chief executive officer, it was reported on Thursday.

Dong joined the company in 2014. She has served in various roles with increasing responsibilities at Eli Lilly & Co in the US, Shanghai United Cell Biotechnology and Shenzhen Kangtai Biological Products Co Ltd.

Dr Chris Chen, chairman of WuXi Vaccines, said, 'We are delighted to announce Jian's new appointment. He is a highly regarded leader with over 30 years of bio-pharmaceutical experience, including vaccine production, process development, as well as the design, construction, qualification and operation management of cGMP manufacturing facilities. We are confident that Jian will lead the company to establish a global high-quality system with outstanding vaccine CDMO capabilities. With a vision to accelerate and transform vaccine development and production, WuXi Vaccines will make substantial contributions to expedite vaccine development and ensure a robust supply chain.'